Compare Johnson & Johnson (JNJ) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Okta, Inc. — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Okta, Inc. trades at $232.13 (market cap $38.50B). The key difference: Johnson & Johnson is far larger — about 16.1× Okta, Inc.'s market cap, and Johnson & Johnson pays a 2.09% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Okta, Inc. for 44 Days on average.
| JNJ | OKTA | |
|---|---|---|
Market Cap | $618.09B | $38.50B |
Volume | 6,050,983 | 2,479,621 |
Sector | Health | Technology |
52-Week High | $278.43 | $232.13 |
52-Week Low | $186.00 | $62.93 |
Typical Hold Time | 129 Days | 44 Days |
Enterprise Value | $646.37B | $36.25B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Okta (OKTA) trades at $220.21, up 1.01% on the day, with a bullish technical signal from moving averages. The stock has consistently beaten earnings estimates in recent quarters. Revenue growth is strong, reaching $2.61B in 2025, with the company achieving positive net income for the first time. Recent news highlights its strategic focus on AI agent security, with announcements at the Oktane 2026 conference generating positive analyst attention.
The outlook is positive, driven by strong fundamentals and Wall Street's bullish consensus, though high valuation multiples and recent insider selling present risks. The key opportunity lies in Okta's positioning in the growing AI security market, while execution against competition remains a challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
